New registry tracks Dupilumab's Real-World impact on COPD
NCT ID NCT07612878
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry will follow 350 COPD patients starting dupilumab (Dupixent) to see how well it works and how safe it is in real life. Researchers will track flare-ups, lung function, and quality of life over 24 months, comparing them to similar patients not on the drug. The goal is to understand who benefits most from this treatment outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, this could confirm that dupilumab helps reduce COPD flare-ups and improve breathing and quality of life in real-world settings.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Dupilumab also has known side effects like injection reactions and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••